HBM Gets Health Boost From Drug Licensing Deals

Dec. 22, 2023 6:00 AM ETHBM Holdings Limited (HBMHF) StockHBMHF, PFE
Bamboo Works
5.01K Followers

Summary

  • Nona Biosciences, a subsidiary of HBM Holdings, has struck a licensing-out deal with Pfizer-owned biotech for an initial sum of $53 million and milestone payments of up to $1.05 billion.
  • HBM Holdings boosted its revenue by 48% in the first half of this year through licensing-out partnerships and by providing R&D services.
  • If HBM’s partnerships start to bear fruit, the company may enjoy more consistent revenue flows and investor attention.

Close up of examining of test sample

deliormanli

As China's pharmaceutical sector battles through tough times, some biotechs are still managing to push ahead with novel drugs and make money along the way.

HBM Holdings Ltd. (OTCPK:HBMHF) (2142.HK), for one, has found strength in numbers, striking drug development

This article was written by

5.01K Followers
Bamboo Works provides news on Chinese companies listed in Hong Kong and the United States, with a strong focus on mid-cap and also pre-IPO companies. Our founding team has more than a century of experience in Chinese and global media and capital markets, working for names including the Wall Street Journal, Reuters, Alibaba and JPMorgan. Drawing on that background, we provide in-depth coverage to drive informed decision-making for investors and others interested in this dynamic group of companies, many of them overlooked by mainstream media.

Recommended For You

About HBMHF Stock

SymbolLast Price% Chg
Market Cap
PE
Yield
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on HBMHF

Related Stocks

SymbolLast Price% Chg
HBMHF
--